GenSight Biologics has submitted an updated regulatory file for its LUMEVOQ® gene therapy to the French medicines safety agency (ANSM). This submission paves the way for the restart of the early access program in France. The company successfully manufactured LUMEVOQ®, blending two GMP drug substance batches to maximize available clinical vials and pass all necessary quality control tests.